MarketWatch (press release) Galvus� (vildagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor, a class of oral diabetes medications that enhance the body's natural ability to control blood sugar. The Galvus� (vildagliptin) safety and efficacy profile has been established in a ... and more »
Family Practice News Digital Network ... and showed a nonsignificant trend toward a higher risk for colorectal cancer (CRC). No association was noted between CRC and thiazolidinedione (TZD), Dr. Siddharth Singh reported at the annual Digestive Disease Week. ... There was considerable ... and more »
MarketWatch (press release) Galvus� (vildagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor, a class of oral diabetes medications that enhance the body's natural ability to control blood sugar. The Galvus� (vildagliptin) safety and efficacy profile has been established in a ... and more »
Family Practice News Digital Network ... and showed a nonsignificant trend toward a higher risk for colorectal cancer (CRC). No association was noted between CRC and thiazolidinedione (TZD), Dr. Siddharth Singh reported at the annual Digestive Disease Week. ... There was considerable ... and more »
MarketWatch (press release) Galvus� (vildagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor, a class of oral diabetes medications that enhance the body's natural ability to control blood sugar. The Galvus� (vildagliptin) safety and efficacy profile has been established in a ... and more »
Family Practice News Digital Network ... and showed a nonsignificant trend toward a higher risk for colorectal cancer (CRC). No association was noted between CRC and thiazolidinedione (TZD), Dr. Siddharth Singh reported at the annual Digestive Disease Week. ... There was considerable ... and more »
NASDAQ Moreover, the drug was well tolerated. We note that Galvus is approved for the treatment of type II diabetes as a monotherapy and in combination with metformin, a sulphonylurea, a thiazolidinedione or insulin, in more than 100 countries including EU ...
PMLiVE The UK's National Institute for Health and Care Excellence (NICE) has recommended the use of Forxiga (dapagliflozin) to treat patients with type 2 diabetes, overturning previous draft guidance that said the drug was not a cost-effective use of NHS ... and more »
